G 207

Drug Profile

G 207

Alternative Names: G207

Latest Information Update: 30 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Georgetown University Medical Center
  • Developer MediGene Inc
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 17 Jan 2008 G 207 is still in phase I trials for Glioma in USA
  • 13 Jun 2005 Phase-I clinical trials in Glioma in USA (Intratumoural)
  • 09 Sep 2003 No development reported - Phase-II for Basal cell cancer in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top